术前抗病毒治疗与HBV相关肝细胞癌微血管侵犯及早期复发的关系
该队列研究纳入2362例接受R0切除的HBV相关肝细胞癌患者,比较术前抗病毒治疗(AVT)与未治疗者的微血管侵犯(MVI)和早期复发。
要点
- 术前高HBV DNA水平(≥2000 IU/mL)是MVI的独立危险因素。
- 术前AVT超过90天与MVI风险降低相关(OR 0.758,95%CI 0.575-0.998)。
- 术前AVT与早期复发风险降低相关(HR 0.732,95%CI 0.605-0.886)。
核心结论
- 术前高HBV DNA水平是MVI的独立危险因素。
- 术前超过90天的抗病毒治疗与HBV相关肝细胞癌部分肝切除术后MVI发生率和早期肿瘤复发率降低相关。
研究设计与样本
- 回顾性队列研究,纳入2008年1月至2010年4月在上海东方肝胆外科医院接受R0切除的2362例HBV相关肝细胞癌患者。
- 中位术后随访44.8个月(四分位距22.8-59.3个月),数据分析时间为2016年6月至2017年10月。
主要发现
- 非AVT组术前HBV DNA≥2000 IU/mL者MVI风险高于<2000 IU/mL者(OR 1.399,95%CI 1.151-1.701)。
关键数值与推荐
- AVT完全应答是MVI的独立保护因素(OR 0.690,95%CI 0.500-0.952)。
- 术前AVT与MVI风险降低相关(OR 0.758,95%CI 0.575-0.998)。
- 术前AVT与早期肿瘤复发风险降低相关(HR 0.732,95%CI 0.605-0.886)。
临床怎么用
- 对HBV相关肝细胞癌拟行部分肝切除患者,术前评估HBV DNA水平并考虑抗病毒治疗。
- 术前抗病毒治疗超过90天可能降低MVI发生率和早期复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A reduced incidence of microvascular invasion (MVI) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) may be associated with a decreased risk of early tumor recurrence and better survival after partial hepatectomy. OBJECTIVE: To examine the association of preoperative antiviral treatment (AVT) with the incidences of MVI and posthepatectomy early tumor recurrence in HBV-related HCC. DESIGN, SETTING, AND PARTICIPANTS: Data on a cohort of 2362 patients who underwent R0 resection for HBV-related HCC between January 2008 and April 2010 at the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China, were reviewed. The median (interquartile range) postoperative follow-up was 44.8 (22.8-59.3) months. Data were analyzed from June 2016 to October 2017. INTERVENTIONS: Preoperative AVT and partial hepatectomy. MAIN OUTCOMES AND MEASURES: Overall survival and time to recurrence after surgery were calculated and compared using the Kaplan-Meier method, log-rank test, and Cox regression analysis. Independent risk factors of MVI presence were assessed by logistic regression analysis. RESULTS: Among 2362 included patients, 1999 (84.6%) were men, and the median (interquartile range) age was 50.6 (43.1-57.3) years. A total of 2036 patients (86.2%) did not receive any preoperative AVT, while 326 (13.8%) received ongoing AVT more than 90 days before surgery. In the non-AVT group, compared with a preoperative HBV DNA level of less than 2000 IU/mL, a preoperative HBV DNA level of 2000 IU/mL or greater was associated with an increased risk of MVI (odds ratio [OR], 1.399; 95% CI, 1.151-1.701). Compared with the non-AVT group, patients receiving AVT had a lower incidence of MVI (38.7% [126 of 326] vs 48.6% [989 of 2036]; P = .001) and reduced risk of MVI (OR, 0.758; 95% CI, 0.575-0.998). A complete response to AVT was an independent protective factor of MVI (OR, 0.690; 95% CI, 0.500-0.952). Accordingly, preoperative AVT was associated with decreased 6-month, 1-year, and 2-year recurrences vs non-AVT (14.2%, 24.6%, and 38.5%, respectively, vs 23.4%, 37.1%, and 52.3%; P < .001); AVT was protective of early tumor recurrence (hazard ratio, 0.732; 95% CI, 0.605-0.886). In addition, patients in the non-AVT group were more likely to have multiple intrahepatic recurrences (49.1% [549 of 1119] vs 36.2% [54 of 149]; P = .003) and recurrences involving multiple hepatic segments compared with patients receiving AVT. CONCLUSIONS AND RELEVANCE: A high preoperative HBV DNA level was an independent risk factor of MVI. Antiviral treatment administered more than 90 days before surgery was associated with reduced incidences of MVI and early tumor recurrence after partial hepatectomy for HBV-related HCC.
引用
- Li Z, Lei Z, Xia Y, et al. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg. 2018. PMID: 30073257. doi:10.1001/jamasurg.2018.2721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。